Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders





Income Statement
Balance Sheet
Cash Flow Statement

Common Size IS
Op Efficiency
Credit Analysis

Inmune Bio, Inc.

Income Statement

Standardized | As Reported Annual | Quarterly | TTM
 
In millions, except per share itemsDec-31-18Dec-31-17
   10-K10-K
Operating expenses:    
Research and development  1.10.4
General and administrative  11.30.5
    Total operating expenses  12.42.1
Loss from operations  -12.4-1.0
   
Other income:    
    Net loss  -12.4-0.8
   
Basic and diluted loss per common share (in dollars per share)  ($1.43)($0.13)
   
Weighted average common shares outstanding, basic and diluted (in shares)  8.76.6
   
COMPREHENSIVE LOSS    
Net loss  -12.4-0.8
Other comprehensive loss - loss on foreign currency translation  0.00.0
    Total comprehensive loss  -12.5-0.8

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy